ACRV - Acrivon Therapeutics, Inc.

QQQ $ 604.92 $ 3.94 (0.66 %)

DIA $ 461.73 $ 2.22 (0.48 %)

SPY $ 665.28 $ 3.75 (0.57 %)

TLT $ 91.09 $ -0.14 (-0.15 %)

GLD $ 391.28 $ -7.46 (-1.88 %)

Previous Close

$ 1.81

Open

$ 1.85

Bid

$ 1.75 x 31

Ask

$ 2.05 x 2,248

Day's Range

$ 1.80 - $ 1.94

52 Week Range

$ 1.05 - $ 8.74

Volume

215,059

Average Volume

Market Cap

37.8M

Beta (5Y Monthly)

$ 1.39

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-13-2025	06-30-2025	10-Q
2	05-14-2025	03-31-2025	10-Q
3	03-27-2025	12-31-2024	10-K
4	11-13-2024	09-30-2024	10-Q
5	08-13-2024	06-30-2024	10-Q
6	05-14-2024	03-31-2024	10-Q
7	03-28-2024	12-31-2023	10-K
8	11-09-2023	09-30-2023	10-Q
9	08-11-2023	06-30-2023	10-Q
10	05-09-2023	03-31-2023	10-Q
11	03-28-2023	12-31-2022	10-K
12	12-15-2022	09-30-2022	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

12 Health Care Stocks Moving In Tuesday's ...
09/09/2025 12:09:28

12 Health Care Stocks Moving In Monday's I...
09/08/2025 17:07:17

why-robinhood-shares-are-trading-higher-by-over-7-here-are-20-stocks-moving-premarket

Why Robinhood Shares Are Trading Higher By...
09/08/2025 09:30:18

12 Health Care Stocks Moving In Friday's A...
09/05/2025 21:06:11

Oppenheimer Maintains Outperform on Acrivo...
08/14/2025 18:08:01

Oppenheimer analyst Matthew Biegler maintains Acrivon Therapeutics (NASDAQ:ACRV) with a Outperform and lowers the price targ...

Acrivon Therapeutics Q2 EPS $(0.55) Beats ...
08/13/2025 20:17:35

Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of ...

Jones Trading Downgrades Acrivon Therapeut...
05/16/2025 20:33:51

Jones Trading analyst Soumit Roy downgrades Acrivon Therapeutics (NASDAQ:ACRV) from Buy to Hold.

Acrivon Therapeutics Q1 EPS $(0.51) Beats ...
05/14/2025 20:28:13

Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of ...

12 Health Care Stocks Moving In Thursday's...
05/01/2025 12:05:58

Acrivon Therapeutics Announces It Will Pre...
04/25/2025 12:09:47

Presentation to highlight how AP3 Generative Phosphoproteomic analyses uncover how ACR-2316 induces mitotic and replicative tum...

12 Health Care Stocks Moving In Wednesday'...
04/16/2025 17:06:28

HC Wainwright & Co. Reiterates Buy on Acri...
03/28/2025 10:43:18

HC Wainwright & Co. analyst Emily Bodnar reiterates Acrivon Therapeutics (NASDAQ:ACRV) with a Buy and maintains $19 pric...

Acrivon Therapeutics Says Cash Runway Exte...
03/27/2025 21:47:20

Acrivon Therapeutics Q4 2024 GAAP EPS $(0....
03/27/2025 21:46:03

Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.60) per share which beat the analyst consensus estimate of ...

12-health-care-stocks-moving-in-wednesdays-after-market-session

12 Health Care Stocks Moving In Wednesday'...
03/26/2025 21:05:44

12-health-care-stocks-moving-in-wednesdays-intraday-session

12 Health Care Stocks Moving In Wednesday'...
03/26/2025 17:05:38

Cantor Fitzgerald Reiterates Overweight on...
03/26/2025 14:11:10

Cantor Fitzgerald analyst Li Watsek reiterates Acrivon Therapeutics (NASDAQ:ACRV) from Overweight to Overweight.

Citizens Capital Markets Reiterates Market...
03/26/2025 12:59:59

Citizens Capital Markets analyst Silvan Tuerkcan reiterates Acrivon Therapeutics (NASDAQ:ACRV) with a Market Outperform and ...

HC Wainwright & Co. Maintains Buy on Acriv...
03/26/2025 10:29:56

HC Wainwright & Co. analyst Emily Bodnar maintains Acrivon Therapeutics (NASDAQ:ACRV) with a Buy and lowers the price ta...

Acrivon Therapeutics To Highlight Differen...
03/19/2025 12:14:20

Event to be held via webcast on March 25, 2025 at 4:00 p.m. ETTo highlight differentiated drug discovery capabilities with its ...